Cervical cancer is the leading cancer killer of African women, driven by HPV inf...
Africa Trials
57
US Trials
3,753
Gap Ratio
66x
Nations
54
Key Finding
Africa hosted 57 cervical cancer trials versus 3,753 in the United States, a 66-fold disparity in research investment.
Regional Comparison
Distribution Analysis
Inequality Profile
Temporal & Structural
Why It Matters
Cervical cancer is the leading cancer killer of African women, driven by HPV infection, yet vaccination and screening trial infrastructure is concentrated in East African research hubs.
The Evidence 136 words · target 156
In the burden-versus-investment landscape of African health research, does the distribution of cervical cancer trials across African nations reveal a systematic research gap? This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.gov through April 2026. Investigators computed the Moran's I spatial autocorrelation as the primary estimand using registry metadata for each nation. Africa hosted 57 cervical cancer trials (0.2% of its portfolio) compared to 3,753 in the United States, yielding a 0.0-fold disparity in per-population investment. Temporal analysis showed 17.1-fold growth in African trial registrations from 2000-2005 to 2021-2025, though the gap with high-income regions persisted. These results expose a fundamental mismatch between where disease burden falls and where research investment flows across Africa. Interpretation is constrained by missing sub-national data and the exclusion of observational studies from the analysis.
Sentence Structure
Question
In the burden-versus-investment landscape of African health research, does the distribution of cervical cancer trials across African nations reveal a systematic research gap?
Dataset
This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.
Method
gov through April 2026.
Primary Result
Investigators computed the Moran's I spatial autocorrelation as the primary estimand using registry metadata for each nation.
Robustness
Africa hosted 57 cervical cancer trials (0.
Interpretation
2% of its portfolio) compared to 3,753 in the United States, yielding a 0.
Boundary
0-fold disparity in per-population investment.
Extra
Temporal analysis showed 17.
Extra
1-fold growth in African trial registrations from 2000-2005 to 2021-2025, though the gap with high-income regions persisted.
Extra
These results expose a fundamental mismatch between where disease burden falls and where research investment flows across Africa.
Extra
Interpretation is constrained by missing sub-national data and the exclusion of observational studies from the analysis.